Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

This study is testing a new drug called HH2853 in people with peripheral T-cell lymphoma (a type of blood cancer) that has relapsed (come back) or stopped responding to previous treatments, to see how safe it is and how well it works. **You may be eligible if...** - You have a confirmed diagnosis of T-cell lymphoma (including types like PTCL-NOS, AITL, ALCL, NKTCL, or other related subtypes) - Your cancer has been treated with at least one prior regimen but has returned or stopped responding - You have received no more than 5 prior lines of treatment - You are in good overall health **You may NOT be eligible if...** - You have not received prior treatment - Your cancer is a type not covered by the study - Your overall health or organ function is too poor Talk to your doctor to see if this trial is right for you.